The dark side of histones: genomic organization and role of oncohistones in cancer.
Cancer
Histone genes
Histone mutations
Histones
Oncohistones
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
07 04 2021
07 04 2021
Historique:
received:
30
12
2020
accepted:
22
03
2021
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
20
1
2022
Statut:
epublish
Résumé
The oncogenic role of histone mutations is one of the most relevant discovery in cancer epigenetics. Recurrent mutations targeting histone genes have been described in pediatric brain tumors, chondroblastoma, giant cell tumor of bone and other tumor types. The demonstration that mutant histones can be oncogenic and drive the tumorigenesis in pediatric tumors, led to the coining of the term "oncohistones." The first identified histone mutations were localized at or near residues normally targeted by post-translational modifications (PTMs) in the histone N-terminal tails and suggested a possible interference with histone PTMs regulation and reading. In this review, we describe the peculiar organization of the multiple genes that encode histone proteins, and the latter advances in both the identification and the biological role of histone mutations in cancer. Recent works show that recurrent somatic mutations target both N-terminal tails and globular histone fold domain in diverse tumor types. Oncohistones are often dominant-negative and occur at higher frequencies in tumors affecting children and adolescents. Notably, in many cases the mutations target selectively only some of the genes coding the same histone protein and are frequently associated with specific tumor types or, as documented for histone variant H3.3 in pediatric glioma, with peculiar tumors arising from specific anatomic locations. The overview of the most recent advances suggests that the oncogenic potential of histone mutations can be exerted, together with the alteration of histone PTMs, through the destabilization of nucleosome and DNA-nucleosome interactions, as well as through the disruption of higher-order chromatin structure. However, further studies are necessary to fully elucidate the mechanism of action of oncohistones, as well as to evaluate their possible application to cancer classification, prognosis and to the identification of new therapies.
Sections du résumé
BACKGROUND
The oncogenic role of histone mutations is one of the most relevant discovery in cancer epigenetics. Recurrent mutations targeting histone genes have been described in pediatric brain tumors, chondroblastoma, giant cell tumor of bone and other tumor types. The demonstration that mutant histones can be oncogenic and drive the tumorigenesis in pediatric tumors, led to the coining of the term "oncohistones." The first identified histone mutations were localized at or near residues normally targeted by post-translational modifications (PTMs) in the histone N-terminal tails and suggested a possible interference with histone PTMs regulation and reading.
MAIN BODY
In this review, we describe the peculiar organization of the multiple genes that encode histone proteins, and the latter advances in both the identification and the biological role of histone mutations in cancer. Recent works show that recurrent somatic mutations target both N-terminal tails and globular histone fold domain in diverse tumor types. Oncohistones are often dominant-negative and occur at higher frequencies in tumors affecting children and adolescents. Notably, in many cases the mutations target selectively only some of the genes coding the same histone protein and are frequently associated with specific tumor types or, as documented for histone variant H3.3 in pediatric glioma, with peculiar tumors arising from specific anatomic locations.
CONCLUSION
The overview of the most recent advances suggests that the oncogenic potential of histone mutations can be exerted, together with the alteration of histone PTMs, through the destabilization of nucleosome and DNA-nucleosome interactions, as well as through the disruption of higher-order chromatin structure. However, further studies are necessary to fully elucidate the mechanism of action of oncohistones, as well as to evaluate their possible application to cancer classification, prognosis and to the identification of new therapies.
Identifiants
pubmed: 33827674
doi: 10.1186/s13148-021-01057-x
pii: 10.1186/s13148-021-01057-x
pmc: PMC8025322
doi:
Substances chimiques
Histones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Références
Nat Genet. 2017 Nov;49(11):1642-1646
pubmed: 28920961
Nucleic Acids Res. 2018 Nov 2;46(19):10007-10018
pubmed: 30053102
Biochemistry. 2005 Oct 4;44(39):12978-89
pubmed: 16185066
Clin Cancer Res. 2016 May 1;22(9):2301-10
pubmed: 26700204
Genes Dev. 2013 May 1;27(9):985-90
pubmed: 23603901
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2808-13
pubmed: 15710904
Science. 2013 May 17;340(6134):823-4
pubmed: 23687038
J Biol Chem. 2015 Jun 26;290(26):15904-8
pubmed: 25944906
Nucleic Acids Res. 2019 Aug 22;47(14):7392-7401
pubmed: 31114907
Blood. 2017 Jan 26;129(4):473-483
pubmed: 28064239
Trends Genet. 2004 Jul;20(7):320-6
pubmed: 15219397
Nucleic Acids Res. 2012 Jul;40(13):5951-64
pubmed: 22467210
Nucleic Acids Res. 2017 Sep 19;45(16):9272-9289
pubmed: 28934504
Acta Neuropathol. 2019 Apr;137(4):637-655
pubmed: 30770999
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Genes Dev. 2017 Dec 1;31(23-24):2313-2324
pubmed: 29352018
Chembiochem. 2008 Jan 4;9(1):77-92
pubmed: 18072184
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
pubmed: 10959836
Epigenetics Chromatin. 2012 Jun 21;5:7
pubmed: 22650316
Nucleic Acids Res. 2018 Sep 28;46(17):8665-8678
pubmed: 30165676
Nat Struct Mol Biol. 2007 Nov;14(11):1070-6
pubmed: 17965724
Nat Struct Mol Biol. 2009 Mar;16(3):304-311
pubmed: 19234465
Cancers (Basel). 2019 May 13;11(5):
pubmed: 31086012
Neurosurgery. 2019 May 1;84(5):1072-1081
pubmed: 29718432
Nature. 2019 Mar;567(7749):473-478
pubmed: 30894748
Nucleic Acids Res. 2012 Nov;40(21):10719-41
pubmed: 23002134
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Biochemistry. 2016 Feb 2;55(4):637-46
pubmed: 26757249
Nucleic Acids Res. 2016 Jul 27;44(13):6127-41
pubmed: 27016736
Nat Med. 2017 Apr;23(4):493-500
pubmed: 28263307
Science. 2013 May 17;340(6134):857-61
pubmed: 23539183
Acta Neuropathol. 2016 Oct;132(4):635-7
pubmed: 27539613
Nat Commun. 2018 May 25;9(1):2080
pubmed: 29802243
Dev Biol. 1987 Sep;123(1):51-8
pubmed: 3622934
Curr Opin Genet Dev. 2006 Apr;16(2):119-24
pubmed: 16503125
EMBO J. 2005 Jun 1;24(11):1911-20
pubmed: 15902274
Sci Rep. 2017 Mar 03;7:43906
pubmed: 28256625
Blood. 2017 Nov 16;130(20):2204-2214
pubmed: 28855157
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9598-9603
pubmed: 30181289
Hum Genet. 1997 Dec;101(3):284-94
pubmed: 9439656
Development. 2001 Mar;128(5):655-64
pubmed: 11171391
Genes Dev. 2014 Apr 1;28(7):672-82
pubmed: 24696452
Gene. 2009 Feb 15;431(1-2):1-12
pubmed: 19059319
Mol Cell. 2012 Aug 24;47(4):596-607
pubmed: 22795134
Nature. 1998 Jun 11;393(6685):599-601
pubmed: 9634239
Epigenetics Chromatin. 2014 Dec 04;7(1):29
pubmed: 25484917
Nat Struct Biol. 2002 Mar;9(3):167-71
pubmed: 11836537
J Biol Chem. 1980 Aug 25;255(16):7610-5
pubmed: 7400135
J Mol Biol. 2018 May 25;430(11):1562-1565
pubmed: 29689253
Curr Opin Genet Dev. 2002 Apr;12(2):162-9
pubmed: 11893489
Nat Rev Genet. 2016 Aug;17(8):487-500
pubmed: 27346641
Mol Cell Biol. 2008 Feb;28(3):1182-94
pubmed: 18025107
Exp Gerontol. 1999 Sep;34(6):741-54
pubmed: 10579635
EMBO Rep. 2006 Jan;7(1):66-71
pubmed: 16258499
Dev Cell. 2005 Jan;8(1):19-30
pubmed: 15621527
Trends Cell Biol. 2011 Sep;21(9):534-42
pubmed: 21741840
Cell Cycle. 2014;13(3):440-52
pubmed: 24275038
Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):436-47
pubmed: 22722606
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Science. 2016 May 13;352(6287):844-9
pubmed: 27174990
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10546-51
pubmed: 12920187
Science. 2015 Oct 16;350(6258):aac4383
pubmed: 26472914
Dev Cell. 2010 Nov 16;19(5):662-74
pubmed: 21074717
EMBO Rep. 2005 Apr;6(4):354-60
pubmed: 15776021
Nat Genet. 2014 May;46(5):451-6
pubmed: 24705254
Nat Genet. 2017 Feb;49(2):180-185
pubmed: 28067913
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Cell. 2004 Jan 23;116(2):259-72
pubmed: 14744436
Brain Pathol. 2017 Nov;27(6):846-850
pubmed: 28378357
Mol Cell Biol. 2006 Feb;26(4):1518-26
pubmed: 16449661
EMBO J. 2007 Aug 8;26(15):3558-69
pubmed: 17627275
EMBO Rep. 2015 Nov;16(11):1439-53
pubmed: 26474902
Nature. 2003 Feb 27;421(6926):961-6
pubmed: 12607005
BMC Struct Biol. 2007 Mar 28;7:17
pubmed: 17391511
Signal Transduct Target Ther. 2020 Mar 6;5(1):27
pubmed: 32296031
Biol Chem. 2005 Jun;386(6):541-51
pubmed: 16006241
Mol Cell. 2015 Jul 2;59(1):75-88
pubmed: 26051178
Mol Cell. 2007 Jan 26;25(2):309-22
pubmed: 17244537
Epigenetics Chromatin. 2011 Jul 20;4:11
pubmed: 21774791
Nat Rev Cancer. 2014 Oct;14(10):
pubmed: 25230881
Genes Dev. 2013 Oct 1;27(19):2109-24
pubmed: 24065740
Front Biosci. 2005 Sep 01;10:2335-45
pubmed: 15970499
Nat Commun. 2016 Apr 28;7:11316
pubmed: 27121947
Cancer Discov. 2019 Oct;9(10):1438-1451
pubmed: 31337617
Cell. 2003 Mar 7;112(5):725-36
pubmed: 12628191
Cancer Cell. 2019 Jan 14;35(1):140-155.e7
pubmed: 30595505
Nat Med. 2014 Dec;20(12):1394-6
pubmed: 25401693
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a019364
pubmed: 25561719
J Cell Biol. 2010 Sep 6;190(5):777-91
pubmed: 20819935
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6845-9
pubmed: 8041707
Eur J Hum Genet. 2020 May;28(5):674-678
pubmed: 31804630
Nat Genet. 2014 May;46(5):462-6
pubmed: 24705250
Cancer Cell. 2019 Oct 14;36(4):402-417.e13
pubmed: 31564638
Nat Rev Genet. 2008 Nov;9(11):843-54
pubmed: 18927579
Science. 2016 Jun 10;352(6291):1344-8
pubmed: 27229140
Nucleic Acids Res. 2008 Apr;36(7):2208-18
pubmed: 18281699
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
Sci Adv. 2018 Oct 31;4(10):eaau5935
pubmed: 30402543
Cancer Cell. 2013 Nov 11;24(5):660-72
pubmed: 24183680
Nat Rev Genet. 2014 Apr;15(4):259-71
pubmed: 24614311
Nat Med. 2017 Apr;23(4):483-492
pubmed: 28263309
Nat Commun. 2012 Feb 14;3:676
pubmed: 22334079
Acta Neuropathol Commun. 2018 Nov 5;6(1):117
pubmed: 30396367
Nucleic Acids Res. 2014 Jun;42(10):6405-20
pubmed: 24753410
Curr Biol. 2002 Oct 29;12(21):1846-51
pubmed: 12419185
J Cell Biol. 1994 Nov;127(3):581-92
pubmed: 7962047
J Mol Biol. 2017 Jun 30;429(13):2075-2092
pubmed: 28322915
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Gene. 1991 Jul 22;103(2):263-8
pubmed: 1889752
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Sci Rep. 2017 Oct 18;7(1):13459
pubmed: 29044188
Nat Cell Biol. 2013 Sep;15(9):1056-66
pubmed: 23873148
Chromosoma. 2011 Jun;120(3):275-85
pubmed: 21274551
FEBS Lett. 2007 Aug 7;581(20):3783-8
pubmed: 17632103
Nat Struct Mol Biol. 2012 Nov;19(11):1139-46
pubmed: 23022728
EMBO J. 2006 Sep 20;25(18):4234-44
pubmed: 16957777
Cell. 2010 Mar 5;140(5):678-91
pubmed: 20211137
Nature. 2004 Jul 29;430(6999):578-82
pubmed: 15282608
Chem Rev. 2015 Mar 25;115(6):2255-73
pubmed: 25495456
Oncogene. 2011 Aug 4;30(31):3391-403
pubmed: 21516126
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2016 Dec;375(22):2206-2208
pubmed: 27959765
Nat Rev Mol Cell Biol. 2017 May;18(5):299-314
pubmed: 28144029
Mol Cell. 2002 Jun;9(6):1191-200
pubmed: 12086617
Genomics. 2002 Nov;80(5):487-98
pubmed: 12408966
Nat Commun. 2016 Oct 03;7:12914
pubmed: 27694942
Genes (Basel). 2018 Jun 20;9(6):
pubmed: 29925815
Epigenetics Chromatin. 2017 Jan 10;10:2
pubmed: 28096900
Brain Pathol. 2013 Sep;23(5):558-64
pubmed: 23414300
Genes Dev. 2016 Jul 15;30(14):1611-6
pubmed: 27474439
PLoS One. 2011 Jan 07;6(1):e15960
pubmed: 21249133
FASEB J. 1994 Dec;8(15):1260-8
pubmed: 8001738
Nat Commun. 2020 Oct 27;11(1):5414
pubmed: 33110075
Mol Cell. 2009 Oct 9;36(1):110-20
pubmed: 19818714
Oncogene. 2017 Jan 19;36(3):373-386
pubmed: 27270440
Chem Res Toxicol. 2003 Dec;16(12):1555-9
pubmed: 14680369
J Biol Chem. 1988 Dec 15;263(35):18972-8
pubmed: 3058692
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062
EMBO J. 2004 Jul 7;23(13):2674-83
pubmed: 15201865
J Cell Biochem. 2004 Jul 1;92(4):691-700
pubmed: 15211567
Nat Genet. 2013 Dec;45(12):1479-82
pubmed: 24162739
Mol Cell. 2005 Apr 1;18(1):123-30
pubmed: 15808514